###begin article-title 0
Cyclophilin A interacts with diverse lentiviral capsids
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 27 32 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 281 286 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 487 492 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 569 574 <span type="species:ncbi:4932">yeast</span>
The capsid (CA) protein of HIV-1 binds with high affinity to the host protein cyclophilin A (CypA). This binding positively affects some early stage of the viral life-cycle because prevention of binding either by drugs that occupy that active site of cyclophilin A, by mutation in HIV-1 CA, or RNAi that knocks down intracellular CypA level diminishes viral infectivity. The closely related lentivirus, SIVcpz also binds CypA, but it was thought that this interaction was limited to the HIV-1/SIVcpz lineage because other retroviruses failed to interact with CypA in a yeast two-hybrid assay.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 35 38 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 87 90 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 188 193 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 214 217 <span type="species:ncbi:11673?1.0">FIV</span>
We find that diverse lentiviruses, FIV and SIVagmTAN also bind to CypA. Mutagenesis of FIV CA showed that an amino acid that is in a homologous position to the proline at amino acid 90 of HIV-1 CA is essential for FIV interactions with CypA.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
These results demonstrate that CypA binding to lentiviruses is more widespread than previously thought and suggest that this interaction is evolutionarily important for lentiviral infection.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 405 406 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 407 408 407 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 632 633 632 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 634 635 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 856 857 856 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 102 107 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 234 239 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 370 375 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 590 595 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin A (CypA) is a highly conserved peptidyl prolyl isomerase (PPIA) that is incorporated into HIV-1 virions and plays a yet undefined role in the early stages of viral replication in some cell types [1-3]. CypA interacts with HIV-1 by virtue of a direct binding between residues in a loop between the fourth and fifth alpha-helices of the capsid (CA) protein of HIV-1 and the active site of CypA [4-6]. Cyclosporin A (CsA), an immunosuppressive drug, binds to the same region of binding groove of CypA and disrupts the CypA/CA interaction which leads to an attenuation of wild type HIV-1 infectivity by 2-5 fold in T cells [7-9]. Although CypA can bind to viral CA in the producer cell during viral assembly, it is CypA in the newly infected target cells that is important for infectivity rather than the CypA that is present in the producer cell [8-11]
###end p 9
###begin p 10
###xml 221 223 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 224 226 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 367 369 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 370 372 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 420 437 412 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aotus trivirgatus</italic>
###xml 614 619 602 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CypA </italic>
###xml 625 627 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 628 630 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 698 700 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 701 703 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 408 418 <span type="species:ncbi:9505">owl monkey</span>
###xml 420 437 <span type="species:ncbi:9505">Aotus trivirgatus</span>
###xml 442 447 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tripartite motif 5 isoform alpha (Trim5alpha) proteins also bind to retroviral CA early after viral entry, and can have a negative effect on the viral lifecycle by accelerating the viral core uncoating or CA degradation [12-15]. Trim5alpha contains a C-terminal B30.2 domain that recognizes retroviral CA and restricts viral replication in a species-specific manner [12,16]. The resistance of cells from the owl monkey (Aotus trivirgatus) to HIV-1 infection is due to the presence of a natural fusion protein in this species, called TrimCyp, in which the B30.2 recognition domain of Trim5alpha was replaced by the CypA gene [17,18]. CypA is important for the activities of some Trim5alpha alleles [19,20].
###end p 10
###begin p 11
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 84 85 84 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 510 511 510 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 684 685 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1442 1444 1442 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1445 1447 1445 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 75 80 <span type="species:ncbi:4932">yeast</span>
###xml 132 137 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 320 325 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 345 366 <span type="species:ncbi:9534">African green monkeys</span>
###xml 421 424 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 460 464 <span type="species:ncbi:11855?1.0">MPMV</span>
###xml 578 583 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 607 612 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 629 635 <span type="species:ncbi:9534">Grivet</span>
###xml 653 676 <span type="species:ncbi:11786">murine leukemia viruses</span>
###xml 756 761 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 827 830 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 919 924 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 991 994 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1108 1113 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1352 1355 <span type="species:ncbi:11673?1.0">FIV</span>
The CypA/CA interaction was initially identified by two-hybrid analysis in yeast [1,5]. In those studies, it was reported that only HIV-1 and the closely related SIVcpz encoded Gag proteins (which are cleaved by viral protease to generate CA during maturation) that could interact with CypA, while the Gag proteins from HIV-2, SIVmac, SIVs from African green monkeys-Sabaeus (SIVagmSAB), feline immunodeficiency viruses (FIV), and Mason-Pfizer monkey viruses (MPMV) failed to interact with CypA in this assay [5]. Furthermore, incorporation of CypA into virions was detected in HIV-1 and SIVcpz, but not in HIV-2, SIVmac, SIVagm-Grivet (SIVagmGRI), and murine leukemia viruses (MLV) [5]. However, here we show that the CypA/CA interaction is not unique to HIV-1/SIVcpz. By both genetic and biochemical experiments we show that FIV can bind CypA and its replication is affected by this interaction to the same extent as HIV-1. Moreover, we have identified an amino acid that is essential for FIV CA interaction with CypA that is in a nearly identical context to an amino acid necessary for the interaction of HIV-1 CA with CypA. Finally, we show that SIVagm-Tantalus (SIVagmTAN) is restricted by TrimCyp, strongly suggesting that this viral CA also interacts with CypA. While these studies were in progress, two other groups also provided evidence that FIV and SIVagm are both susceptible to the TrimCyp restriction in a CsA sensitive manner [21,22]. Together, these results demonstrate that lentiviral interactions with CypA are more conserved than had been previously assumed and suggest that CypA/CA interactions play an evolutionarily conserved role in the life cycle of many lentiviruses.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 0 3 <span type="species:ncbi:11673?1.0">FIV</span>
FIV CA interacts with CypA
###end title 13
###begin p 14
###xml 461 463 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 186 191 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 196 199 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 326 331 <span type="species:ncbi:9606">human</span>
###xml 336 343 <span type="species:ncbi:9491">Tamarin</span>
###xml 570 573 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 593 598 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We began this study by looking at the pattern of restriction effect of Trim5alpha isolated from diverse primate species with a panel of different retroviruses. Remarkably, we found that HIV-1 and FIV had an identical pattern of restriction in that both were strongly restricted by rhesus Trim5alpha, had slight sensitivity to human and Tamarin Trim5alpha, and were resistant to Titi Trim5alpha (data not shown). Similar data was also reported by another group [23]. Because Trim5alpha restriction, like the CypA interaction, is dictated by CA, this led us to examine if FIV is also similar to HIV-1 in its interaction with CypA.
###end p 14
###begin p 15
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 532 533 532 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 551 552 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 825 826 825 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 863 865 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 989 991 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1080 1082 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1212 1214 1212 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 25 36 <span type="species:ncbi:9505">owl monkeys</span>
###xml 56 61 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 122 127 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 282 285 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 460 465 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 469 474 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 541 544 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 871 876 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1026 1031 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1099 1102 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1122 1127 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The TrimCyp protein from owl monkeys strongly restricts HIV-1 because the C-terminal CypA portion of the protein binds to HIV-1 CA, while the N-terminal portion of the protein leads to premature uncoating or degradation of incoming virions [13,14,17,18]. We therefore asked whether FIV is also sensitive to TrimCyp restriction as an indirect measure of CA-CypA recognition. Cells expressing TrimCyp were generated and infected with VSV-G pseudotyped wild-type HIV-1, a HIV-1 G89V mutant (CA with a G89V mutation does not bind CypA [2]), and FIV (Fig. 1). Infections were done in the presence or absence of CsA to verify the dependence of the restriction on CypA function. Because infections were done with viruses that encode GFP (see Methods), the number of infected cells could be directly analyzed by flow cytometry (Fig. 1). Consistent with previous reports [17,18], HIV-1 is sensitive to TrimCyp restriction and the restriction can be neutralized by treatment of cells with CsA (Fig. 1A), while the negative control, the HIV-1 G89V mutant, is not restricted by TrimCyp (Fig. 1B). We found that FIV behaves similar to HIV-1 in that it was restricted by TrimCyp, and this restriction is reversed by CsA (Fig. 1C).
###end p 15
###begin p 16
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Infectivity of HIV-1 WT, G89V mutant and FIV under the TrimCyp restriction</bold>
###xml 15 20 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 41 44 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 123 128 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 144 149 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 164 167 <span type="species:ncbi:11673?1.0">FIV</span>
Infectivity of HIV-1 WT, G89V mutant and FIV under the TrimCyp restriction. CRFK and CRFK-TrimCyp cells were infected with HIV-1 wild-type (A), HIV-1 G89V (B), and FIV (C) in the presence or absence of CsA. The infected cells were analyzed by flow cytometry and the infectivity is presented as percentage of cells that were GFP+ (on a log scale).
###end p 16
###begin p 17
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1016 1025 1016 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1031 1033 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1145 1147 1145 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1185 1187 1185 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 42 45 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 170 173 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 296 301 <span type="species:ncbi:9606">human</span>
###xml 526 529 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 629 634 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 725 730 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 832 837 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 913 916 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 936 939 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1012 1015 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1080 1083 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1308 1311 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1318 1323 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
These results with TrimCyp suggested that FIV does indeed interact with CypA. In order to test this directly, we used an assay to biochemically detect binding of CypA to FIV CA (Fig. 2). Thus, 293T cells were transiently transfected with a plasmid that expressed a fusion protein between GST and human CypA (GST-CypA) or with GST alone. Cell lysates were then incubated with glutathione beads to partially purify the GST proteins from the cell extracts. After washing to remove unbound proteins, the beads were incubated with FIV virions, and the GST-bound proteins were run on SDS-PAGE gels and blotted with anti-CA antibodies. HIV-1 WT and G89V were used as the positive and negative controls for this assay, respectively. HIV-1 wild type associates with CypA because it is pulled down by the GST-CypA fusion protein, whereas the HIV-1 G89V mutant does not bind to GST-CypA (data not shown). On the other hand, FIV behaves similar to HIV in that partially purified GST-CypA, but not GST alone, is able to bind FIV in vitro (Fig. 2A). This binding is dose-dependent (adding more FIV virions increases the amount of CA that is pulled-down, Fig. 2B, top), and is sensitive to CsA (Fig. 2B, bottom). Thus, by both genetic (TrimCyp restriction) and biochemical (GST-CypA pull-downs) assays, we demonstrate that FIV, like HIV-1, interacts with CypA.
###end p 17
###begin p 18
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Biochemical interaction of CypA and FIV CA</bold>
###xml 36 39 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 262 265 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 298 301 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 380 383 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 452 455 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 559 562 <span type="species:ncbi:11673?1.0">FIV</span>
Biochemical interaction of CypA and FIV CA. (A) GST-CypA or control GST fusion proteins were generated in 293T cells. After the incubation of the 293T cell lysates with glutathione beads, the beads were washed to remove unbound proteins, and then incubated with FIV virions. After removing unbound FIV virions by washing, beads were subjected to the SDS-PAGE and probed with anti-FIV CA antibodies for the detection of the interaction between CypA and FIV CA. (B) was conducted with the same experimental protocol for (A), but with different amounts of input FIV virions (serial dilution) in the presence or absence of 10 muM of CsA.
###end p 18
###begin title 19
###xml 14 17 <span type="species:ncbi:11673?1.0">FIV</span>
Proline 90 on FIV capsid is an essential amino acid for Cyclophilin A binding
###end title 19
###begin p 20
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 61 66 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 159 162 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 259 262 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 353 356 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 370 375 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 393 396 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 712 715 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The glycine at position 89 and the proline at position 90 on HIV-1 capsid are the most critical target amino acids of CypA binding [2]. Since we observed that FIV also interacts with CypA, we next tried to identify if amino acids in a similar region of CA of FIV are also critical for the CypA recognition. By aligning the capsid amino acid sequence of FIV with that of HIV-1, we noticed that FIV capsid contains five prolines on the loop between the predicted alpha-helices 4 and 5 (Fig. 3A). Each of these five proline residues was individually mutated to alanine. In addition, arginine at position 89 was also mutated to alanine because this position corresponds to the critical glycine at position 89 in the HIV CA (Fig. 3A).
###end p 20
###begin p 21
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CypA/CA interaction in FIV WT and mutants</bold>
###xml 23 26 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 87 90 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 96 101 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 229 232 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 538 541 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 578 581 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 687 690 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 720 723 <span type="species:ncbi:11673?1.0">FIV</span>
CypA/CA interaction in FIV WT and mutants. (A) The CA amino acid sequence alignment of FIV with HIV-1. The proline to alanine and the arginine to alanine mutations are in bold, and gaps are indicated with "-". (B) Infectivity of FIV wild type and mutants under the TrimCyp restriction. FIVs wild type and mutants were transduced to CRFK or CRFK-TrimCyp cells to test their sensitivity to TrimCyp restriction. The % GFP determined by flow cytometry is the readout of the infectivity. (C) GST-CypA pull-down of CA from wild type and mutant FIV. The upper panel shows 10% of input FIV virions used for the GST-CypA pull-down assay, and the lower panel shows the CA pulled down by GST-CypA. FIV virions are detected by anti-FIV CA antibody.
###end p 21
###begin p 22
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 337 340 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 861 864 <span type="species:ncbi:11673?1.0">FIV</span>
These constructs were then co-transfected to 293T cells with VSV-G and GFP reporter plasmids to generate VSV-G pseudotyped FIVs that were used to infect CRFK or CRFK-TrimCyp cells. The infectivity of each virus was normalized to give an amount of virus that resulted in about the same number of infected CRFK cells. Similar to wild-type FIV, the mutations P84A, P85A, P88A, P92A, and R89A are also restricted by TrimCyp (Fig. 3B). Moreover, in each case, the restriction by TrimCyp is abrogated by the addition of CsA. These data indicate that mutating each of these residues did not destroy a functional interaction between CypA and the viral CA. However, the P90A mutant is not sensitive to the TrimCyp restriction and the infectivity is not affected by the addition of CsA. This indicates that amino acid P90 is critical for a functional interaction between FIV CA and CypA (Fig. 3B).
###end p 22
###begin p 23
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 115 118 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 132 135 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 274 277 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 592 595 <span type="species:ncbi:11673?1.0">FIV</span>
In addition to the TrimCyp assay, we also applied the GST-CypA pull down assay to test the interaction of CypA and FIV mutants. The FIV wild type and mutant virions were incubated with the GST-CypA and the interactions were analyzed by Western Blotting (Fig. 3C). Wild-type FIV and other mutants are sensitive to the TrimCyp restriction and are pulled down by the GST-CypA. On the other hand, the P90A mutant, which is not sensitive to the TrimCyp restriction, is also not pulled down by GST-CypA (Fig. 3C). These data demonstrate that amino acid P90 is a critical target for CypA binding to FIV CA.
###end p 23
###begin title 24
###xml 13 16 <span type="species:ncbi:11673?1.0">FIV</span>
CypA affects FIV infection
###end title 24
###begin p 25
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 320 321 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 488 489 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 581 582 581 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 722 724 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 851 852 847 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 926 927 922 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 984 985 980 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 67 70 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 130 135 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 193 198 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 355 358 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 444 447 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 534 539 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 624 627 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 685 690 <span type="species:ncbi:9606">human</span>
###xml 717 720 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 747 752 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 773 776 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 882 885 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1024 1027 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1034 1039 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Previous reports showed that CsA decreases spreading infections of FIV in cells and in animals [24,25]. However, comparisons with HIV-1 were not done. It has been shown that the infectivity of HIV-1 drops 2-5 fold when the CypA/CA interaction is blocked by CsA in Jurkat T cells in single-cycle infection experiments [7-9]. To examine the role of CypA in FIV infection in the same cell type, Jurkat T cells were infected with VSV-G-pseudotyped FIV in the presence or absence of CsA (Fig. 4). As expected, the infectivity of wild type HIV-1 was reduced by the addition of CsA (Fig. 4, top). We obtained reduced infections of FIV in Jurkat cells relative to CRFK cells presumably due to human Trim5alpha restriction of FIV [23]. However, similar to HIV-1, the infectivity of FIV decreased further by 2-5 fold when CsA was present during infection (Fig. 4, middle). The P90A mutant of FIV which fails to bind cyclophilin A (Fig. 3), in contrast, was not sensitive to CsA treatment (Fig. 4, bottom). These results indicate that FIV, like HIV-1, requires the endogenous cyclophilin A in target cells for optimal infection.
###end p 25
###begin p 26
###xml 0 26 0 26 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The CypA-dependency of FIV</bold>
###xml 23 26 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 83 86 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 106 109 <span type="species:ncbi:11673?1.0">FIV</span>
The CypA-dependency of FIV. Jurkat T cells were infected with HIV-1 wild-type (A), FIV wild-type (B), and FIV P90A (C) in the presence or absence of 1.25 muM of CsA. All viruses were first normalized on CRFK cells and equivalent CRFK infectious units were used and are plotted on the X-axis. For example, the amount of virus that gave 20% GFP positive cells on CRFK cells is 0.2 on the X-axis. The infected Jurkat cells were analyzed by flow cytometry and the infectivity is presented as % GFP+ cells.
###end p 26
###begin title 27
SIVagmTAN also binds to CypA
###end title 27
###begin p 28
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 170 173 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 264 269 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 522 527 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 532 535 <span type="species:ncbi:11673?1.0">FIV</span>
We aligned the amino acids in the region between the prediced alpha-helices 4 and 5 of CA from a number of different lentiviruses, and noticed that SIVagmTAN, similar to FIV, has 5 prolines, and that the length of the SIVagmTAN loop (9 amino acids) is the same as HIV-1 (Fig. 5A). We therefore tested whether SIVagmTAN also interacts with CypA using the TrimCyp assay (Fig. 5B). Consistent with other reports [5,6], SIVmac, as a negative control, is not sensitive to the TrimCyp. On the other hand, SIVagmTAN behaves like HIV-1 and FIV. The infectivity of SIVagmTAN is strongly restricted by TrimCyp protein, and the restriction can be counteracted by the treatment of CsA (Fig. 5B). This result suggests that the CA of SIVagmTAN is also recognized by the CypA, and that the ability of CypA to recognize lentiviral capsids is widespread, although not universal, among lentiviruses.
###end p 28
###begin p 29
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CypA/CA interaction in SIVmac, HIV-1, and SIVagmTAN</bold>
###xml 31 36 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 79 84 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 194 199 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 273 278 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 379 384 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CypA/CA interaction in SIVmac, HIV-1, and SIVagmTAN. (A) Sequence alignment of HIV-1 and other lentiviruses. The amino acid sequences of the loop between alpha helices 4 and 5 were aligned with HIV-1. Prolines are in bold, and gaps are indicated as "-". (B) Infectivity of HIV-1, SIVmac, and SIVagmTAN under the TrimCyp restriction. CRFK or CRFK-TrimCyp cells were infected with HIV-1-luc, SIVmac-luc, and SIVagmTan-luc, and the infectivity was determined by luminometer.
###end p 29
###begin title 30
Discussion
###end title 30
###begin p 31
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 64 69 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 171 174 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 255 258 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 335 340 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 420 423 <span type="species:ncbi:11673?1.0">FIV</span>
The CypA/CA interactions had originally been described only for HIV-1 and SIVcpz [5]. Here, we show that this phenotype is more widespread among lentiviruses because both FIV and SIVagmTAN also interact with CypA. Moreover, we identified an amino acid in FIV CA that is critical for CypA binding that is in a similar position in CA of HIV-1. Finally, we show that the CypA/CA interaction is functionally significant for FIV replication.
###end p 31
###begin p 32
###xml 45 46 45 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 81 82 81 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 257 265 257 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. Coli </italic>
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 456 464 456 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. Coli </italic>
###xml 120 123 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 186 191 <span type="species:ncbi:4932">yeast</span>
###xml 379 382 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 421 424 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 446 451 <span type="species:ncbi:4932">yeast</span>
It is not clear why a functional assay (Fig. 1) and a direct binding assay (Fig. 2) detected the CypA/CA interaction in FIV, whereas previous reports that looked for interactions with a yeast-two hybrid assay or by expression of recombinant Gag and CypA in E. Coli did not [5]. It is possible that the formation of mature viral core may be more important for CypA recognition of FIV, or that subtle folding problems with FIV Gag was expressed in yeast and E. Coli might have prevented binding. Nonetheless, the two assays used here (TrimCyp restriction and GST-CypA pull down) were conducted in mammalian cells and thus more closely mimic the structure of CA found in natural targets cells.
###end p 32
###begin p 33
###xml 17 20 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 162 167 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The finding that FIV and SIVagmTAN also bind host CypA demonstrates that the CypA/CA interaction is a more wide spread phenotype among lentiviruses than just the HIV-1/SIVcpz lineage. At this point it is not possible to determine if this property arose independently in three separate lentivirus lineages, or if an ancestral retrovirus was able to bind CypA and then other lentiviruses (for example, SIVmac) each lost this ability. Although the latter possibility is more parsimonious, it will be important to test a much broader range of lentiviruses for CypA binding. It is also possible that the ability of a lentivirus to bind CypA is evolutionarily dynamic and changes upon adaptation to new hosts.
###end p 33
###begin p 34
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 861 862 861 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1296 1297 1296 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1298 1299 1298 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 51 54 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 132 137 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 287 292 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 443 448 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 618 623 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 746 751 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 807 812 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 843 848 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 936 941 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1278 1283 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1344 1349 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We determined that the proline at amino acid 90 on FIV CA is critical for the interaction with CypA. This is similar to the site on HIV-1 that binds CypA, suggesting the proline in the middle of the loop is crucial for CypA recognition. However, the CA sequence alignment of SIVmac with HIV-1 shows that SIVmac also possesses this corresponding proline (Fig. 5A). The major difference of the loop between the fourth and fifth alpha-helices in HIV-1 and SIVmac is its length. We applied the SWISS-MODEL computer modelling to generate putative structure of CA from SIVmac and SIVagmTAN based on the crystal structure of HIV-1 CA bound to CypA (PDB:1AK4). We found that the CypA-binding loop of SIVagmTAN can be superimposed on the parallel loop of HIV-1 well, while the loop of SIVmac is shorter than that of HIV-1 and is not able to fit in the HIV-1 scale (Fig. 6). This suggests that in addition to the proline at position 90 (based on HIV-1), the length of the loop also contributes to the CypA binding. A shorter loop might not be able to insert into the binding groove of CypA even though the target proline is present in the middle of the loop. On the other hand, Cyclophilin B (CypB), another member in the cyclophilin family, was showed to interact with Gag proteins from HIV-1 and SIVmac [1,2]. However, the CypB/Gag interaction in both HIV-1 and SIVmac is not mediated by binding of CypB to the same loop that CypA recognizes. To our knowledge, the CypB/Gag interaction has not been reported to affect viral replication.
###end p 34
###begin p 35
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Computer modelling of the CA structure from SIVmac and SIVagmTAN</bold>
###xml 118 123 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 263 268 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 320 325 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Computer modelling of the CA structure from SIVmac and SIVagmTAN. The CA structure from SIVmac and SIVagmTAN by using HIV-1 CA crystal structure (PDB:1AK4) as template. The CA from SIVmac (upper panel) and SIVagmTAN (lower panel) were superimposed on the CA from HIV-1 which binds to CypA. The proline at position 90 on HIV-1 CA is indicated.
###end p 35
###begin p 36
###xml 208 210 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 211 213 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 214 216 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 217 219 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 320 322 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 323 325 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 605 607 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 608 610 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 611 613 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 996 998 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 999 1001 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1449 1451 1417 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1831 1833 1783 1785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 359 364 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 403 408 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 494 499 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 560 580 <span type="species:ncbi:9534">African green monkey</span>
###xml 703 708 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 737 757 <span type="species:ncbi:9534">African green monkey</span>
###xml 808 828 <span type="species:ncbi:9534">African green monkey</span>
###xml 849 854 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 885 890 <span type="species:ncbi:9606">Human</span>
###xml 939 944 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1251 1271 <span type="species:ncbi:9534">African green monkey</span>
###xml 1280 1285 <span type="species:ncbi:9606">human</span>
###xml 1442 1447 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1484 1504 <span type="species:ncbi:9534">African green monkey</span>
###xml 1574 1579 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1608 1628 <span type="species:ncbi:9534">African green monkey</span>
The exact role of CypA/CA interaction in HIV-1 life cycle is still not clear. However, several groups have suggested that CypA/CA interaction mediates the lentiviral susceptibility to Trim5alpha restriction [17-19,26,27]. The discovery of TrimCyp links the CypA/CA interaction with the post-entry restriction mechanism [17,18]. The potent restriction against HIV-1 infection requires the recognition of HIV-1 CA by the C-terminal CypA domain of TrimCyp. In addition, the CypA/CA interaction in HIV-1 was shown to correlate with viral sensitivity to rhesus and African green monkey Trim5alpha restriction [19,26,27]. Blocking CypA/CA interaction by CsA or down-regulating endogenous CypA by RNAi rescues HIV-1 replication from rhesus and African green monkey Trim5alpha restriction, suggesting the rhesus and African green monkey Trim5alpha restrict HIV-1 via the CypA-binding pathway. Human Trim5alpha, on the other hand, weakly restricts HIV-1 via a pathway that is independent of CypA binding [26-28]. It is not clear whether the Trim5alpha restriction is mediated by direct binding to CypA or requires an unidentified adaptor protein. Another explanation is that CypA/CA interaction changes the CA conformation which provides access for rhesus and African green monkey but not human Trim5alpha. We report here that SIVagmTAN interacts with CypA, but it has a different recognition pattern by different Trim5alpha proteins when compared to HIV-1 [29]. SIVagmTAN is resistant to the African green monkey Trim5alpha but susceptible to rhesus Trim5alpha restriction, whereas HIV-1 is restricted by rhesus and African green monkey Trim5alpha via the CypA-binding pathway. The SIVagmTAN susceptibility to rhesus Trim5alpha is probably determined by the patch on the B30.2 domain and the CypA/CA has little to do with the restriction [30].
###end p 36
###begin p 37
###xml 56 61 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 99 104 <span type="species:ncbi:9606">human</span>
###xml 164 167 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 206 212 <span type="species:ncbi:9606">humans</span>
CypA binding is necessary for Trim5alpha restriction of HIV-1 in rhesus cells, but not for that in human cells. It has been hypothesized that CypA binding protects HIV from an unknown restriction factor in humans. If so, then this hypothesis would have to be extended to account for the fact that diverse lentiviruses also bind CypA. Our report here will provide a parallel line to investigate the role that CypA plays in lentiviral life cycle.
###end p 37
###begin title 38
Methods
###end title 38
###begin title 39
Cells
###end title 39
###begin p 40
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 110 116 <span type="species:ncbi:9913">bovine</span>
###xml 217 243 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
293T and CRFK (Crandall Feline Kidney) cells were cultured in Dulbecco's modified Eagle medium with 10% fetal bovine serum (FBS). Jurkat T cells were grown in RPMI with 10% FBS. 293T cells were used for generation of vesicular stomatitis virus G protein (VSV-G) pseudotyped lentiviruses and for production of GST-CypA fusion proteins. CRFK cells expressing TrimCyp protein from different species were generated as described previously [30].
###end p 40
###begin title 41
Generation of VSV-G pseudotyped lentiviruses
###end title 41
###begin p 42
###xml 8 10 8 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 130 135 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 144 149 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 167 172 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 309 312 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 366 370 <span type="species:ncbi:162683">Mayo</span>
###xml 444 447 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1160 1163 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1177 1180 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1409 1412 <span type="species:ncbi:11673?1.0">FIV</span>
2.5 x 105 cells/ml of 293T cells were plated in 2 ml/well in a 6-well plate 16 hours prior to transfection. The VSV-G pseudotyped HIV-1 WT-GFP, HIV-1 G89V-GFP mutant, HIV-1 WT-Luc, SIVmac-Luc, and SIVagmTAN-Luc were generated as described previously [30,31]. Plasimds pFGinSin and pFP93 [32] used to generate FIV vectors and virions were gifts of Eric Poeschla (The Mayo Clinic College of Medicine, Rochester). For generating VSV-G pseudotyped FIV WT-GFP, 0.75 mug of enhanced green fluorescent protein transfer vector pFGinSin was co-transfected with 0.4 mug of pL-VSV-G, 0.1 mug of pCMV-tat, and 0.75 mug of pFP93 to 293T cells by FuGene 6 transient transfection. For generating the VSV-G pseudotyped mutant FIVs, the same method was applied but replacing pFP93 with pFP93 proviral DNA with mutations of P84A, P85A, P88A, P90A, P92A, and R89A. The mutations were generated with the QuickChange Site-directed mutagenesis kit by following the instruction of manufacturer's protocol (Stratagene). Culture media were collected on 48 hours, 72 hours, and 96 hours after transfection, and were passed through a 0.2 mum filter (Nalgene) for harvesting the viruses. FIV P84A-GFP and FIV P90A-GFP were ultra-centrifuged in an SW28 rotor at 23000 rpm for 1.5 hours for concentrating viruses 10-fold and 100-fold, respectively. All viruses were aliquoted in 1.5 ml micro-tubes and frozen at -80degreesC until use. The FIV viral titer was tested by infecting CRFK cells with different volumes of the original viral stocks; the amount of virus causing 20% GFP+ (20% infected cells) was defined as 0.2 CRFK infectious equivalents.
###end p 42
###begin title 43
Infection
###end title 43
###begin p 44
###xml 107 109 107 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 282 284 282 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 516 518 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 739 744 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 753 758 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 983 987 <span type="species:ncbi:9913">calf</span>
###xml 1080 1085 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CRFK or CRFK cells expressing TrimCyp proteins were plated 16 hours before infection at a density of 8 x 104 cells/ml on a 12-well (1 ml/well) or a 24-well (0.5 ml/well) plate. Jurkat T cells for the CypA-dependency experiment were prepared before infection at a density of 2.5 x 105 cells/ml on a 12-well (1 ml/well) plate. The VSV-G pseudotyped viruses were added to target cells in the presence of 20 mug/ml DEAE/Dextran, and spinoculated at 1200 relative centrifugal force (rcf) at room temperature for 2 hours [33]. The infected cells were placed at 37degreesC incubator for 48 hours until the analysis of the infectivity tested with flow cytometry (for viruses expressing GFP) or luminometer (for viruses expressing luciferase). The HIV-1 WT-GFP, HIV-1 G89V-GFP, and all FIVs (WT and mutants) infected cells was harvested and fixed with 1% paraformaldehyde for 1 hour at 4degreesC. The fixed cells were washed with PBS and re-suspended with 300 mul of PBS supplemented with 5% calf serum, and subjected to FACScan (Becton Dickinson) for the analysis of the infectivity. The HIV-1 WT-Luc, SIVmac-Luc, and SIVagmTAN-Luc infected cells were washed with PBS and lyzed with 80 mul of the cell culture lysis buffer (Promega), and 10 mul of the lysates were used for the measurement of luciferase activity (infectivity) with the Luciferase assay system (Promega) and luminometer.
###end p 44
###begin title 45
GST-CypA pull down assay
###end title 45
###begin p 46
###xml 385 387 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 70 75 <span type="species:ncbi:9606">human</span>
###xml 101 106 <span type="species:ncbi:9606">human</span>
###xml 483 488 <span type="species:ncbi:9606">human</span>
###xml 1409 1414 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1419 1422 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1431 1434 <span type="species:ncbi:11673?1.0">FIV</span>
The mRNA from 293T cells were extracted with RNeasy kit (Qiagen). The human CypA was cloned from the human mRNA by using the OneStep RT-PCR (Qiagen) with primer sets 5'-GGATCCACGGTTCAGGTGGTTCTGGAGGTTCAGGAGTCAACCCCACCGTGTTC-3' (forward) and 5'-CTCGAGTTATTCGAGTTGTCCACAGTCAGCAATGGT-3' (reverse). The cyclophilin cDNA was used to replace huTrim5alpha in the plasmid pEF/GST-huTrim5alpha [34] (a kind gift of Jeremy Luban, Columbia University, New York). To generate GST-CypA protein in human cells, 1 mug of pEF/GST-CypA or pEF/GST were transiently transfected to 293T cells with FuGene 6 (Roche). 72 hours after transfection, one 6-well plate of cells were harvested and lysed with 1.6 ml of GST buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.5% NP40, 0.1% SDS, and supplemented with complete protease inhibitor). The lysates were centrifuged at 13200 rpm for 1 minute, and the supernatants were harvested. To balance the glutathione-sepharose beads (BD Biosciences) for optimal binding, 200 mul of beads were centrifuged at 5000 rpm for 5 minutes and washed with 800 mul of GST buffer for 3 times. The beads were re-suspended with 200 mul of GST buffer and incubated with 800 mul of GST or GST-CypA supernatants at 4degreesC on a slowly rotated shaker for 1 hour. After incubation, beads were centrifuged at 5000 rpm for 5 minutes and washed three times with 800 mul of GST buffer. Viruses for the pull down assay (HIV-1 WT, FIV WT, and FIV mutants) were prepared by concentrating the same amount of virions (about 1 ml) into 200 mul of PBS. The concentrated virions then were incubated with the GST or GST-CypA bound beads at 4degreesC on a slowly rotated shaker for 1 hour. Beads were centrifuged and washed with 800 mul of GST buffer for 3 times. The beads then were re-suspended with 60 mul of GST buffer and frozen at -80degreesC until the Western blot analysis.
###end p 46
###begin title 47
Western blot analysis
###end title 47
###begin p 48
###xml 148 150 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 452 457 <span type="species:ncbi:10090">mouse</span>
###xml 463 466 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 713 724 <span type="species:ncbi:3704">horseradish</span>
###xml 752 757 <span type="species:ncbi:10090">mouse</span>
Lysates from the GST-pull down assay were mixed with 20 mul of sample buffer (2% SDS, 1% 2-mercaptomethanol, 1% glycerol, 65 mM Tris-hydrochloride [34]). 30 mul of the mixture were loaded on SDS-10% polyacrylamide gels. After electrophoresis, the proteins were transferred to polyvinylidene difluoride membranes. The membranes were blocked for 30 minutes at room temperature with 5% fat-free milk in PBS, and then incubated with a 1:1000 dilution of a mouse anti-FIV capsid monoclonal antibody (clone 2C1, from NIH AIDS Research and Reference Reagent program) overnight at 4degreesC. The membranes were washed 10 minutes for 3 times in PBS containing 0.1% Tween 20 and then incubated with a 1:10000 dilution of a horseradish peroxidase-conjugated anti-mouse monoclonal antibody (Santa Cruz Biotechnology) for 30 minutes at room temperature. The membranes were washed 3 times for 30 min, and the bound antibody was detected with the ECL detection system (Amersham).
###end p 48
###begin title 49
Sequence alignment and structure computer modeling
###end title 49
###begin p 50
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 81 86 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 141 144 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 404 409 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 425 430 <span type="species:ncbi:9606">human</span>
Lentiviral Gag sequences were from GenBank. The accession numbers are: HIV-1 (), HIV-2 (), SIVcpz (), SIVmac (), SIVsm (), SIVagmTAN (), and FIV (). The CA sequences from these lentiviruses were aligned by the ClustalX software [35,36]. The computer modeling of N-terminal CA structure from SIVmac and SIVagmTAN was performed with the SWISS-MODEL server [37, 38, 39] by using the CA crystal structure of HIV-1 which bound to human CypA (PDB:1AK4) [4]. The predicted CA structures were viewed and displayed by DeepView (Swiss Pdb-Viewer).
###end p 50
###begin title 51
Competing interests
###end title 51
###begin p 52
The author(s) declare that they have no competing interests.
###end p 52
###begin title 53
Authors' contributions
###end title 53
###begin p 54
TYL and ME designed the experiments. TYL performed the experiments. TYL and ME analyzed the data and wrote the paper.
###end p 54
###begin title 55
Acknowledgements
###end title 55
###begin p 56
###xml 129 132 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 291 294 <span type="species:ncbi:11673?1.0">FIV</span>
We thank two rotation students, Olivier Humbert and Jon Reed, for initial experiments in this project to test the sensitivity of FIV to Trim5alpha and to TrimCyp, the FHCRC Flow Cytometry lab, Jeremy Luban and the NIH AIDS Reagent Repository for the TrimCyp construct, Eric Poeschla for the FIV GFP vector and packaging construct, and Eric Poeschila, Semih Tareen, Masahiro Yamashita, and Yegor Voronin for comments on the manuscript.
###end p 56
###begin p 57
This work was supported by NIH grant R37 AI30937 to M.E.
###end p 57
###begin article-title 58
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B
###end article-title 58
###begin article-title 59
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Specific incorporation of cyclophilin A into HIV-1 virions
###end article-title 59
###begin article-title 60
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Functional association of cyclophilin A with HIV-1 virions
###end article-title 60
###begin article-title 61
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 79 84 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid
###end article-title 61
###begin article-title 62
###xml 57 92 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 94 99 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 105 138 <span type="species:ncbi:11723">simian immunodeficiency virus SIV</span>
###xml 163 168 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses
###end article-title 62
###begin article-title 63
###xml 16 21 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 50 79 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 85 99 <span type="species:ncbi:9544">Macaca mulatta</span>
Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence
###end article-title 63
###begin article-title 64
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction
###end article-title 64
###begin article-title 65
###xml 36 71 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity
###end article-title 65
###begin article-title 66
###xml 39 74 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells
###end article-title 66
###begin article-title 67
###xml 39 44 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells
###end article-title 67
###begin article-title 68
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors
###end article-title 68
###begin article-title 69
Control of viral infectivity by tripartite motif proteins
###end article-title 69
###begin article-title 70
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor
###end article-title 70
###begin article-title 71
###xml 65 70 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Proteasome inhibitors uncouple rhesus TRIM5 alpha restriction of HIV-1 reverse transcription and infection
###end article-title 71
###begin article-title 72
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys
###end article-title 72
###begin article-title 73
Retrovirus restriction factors
###end article-title 73
###begin article-title 74
###xml 53 63 <span type="species:ncbi:9505">owl monkey</span>
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1
###end article-title 74
###begin article-title 75
###xml 46 56 <span type="species:ncbi:9505">owl monkey</span>
###xml 83 88 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1
###end article-title 75
###begin article-title 76
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells
###end article-title 76
###begin article-title 77
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin A: An auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1
###end article-title 77
###begin article-title 78
###xml 92 97 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1
###end article-title 78
###begin article-title 79
###xml 28 33 <span type="species:ncbi:9606">human</span>
Antiretroviral potential of human tripartite motif-5 and related proteins
###end article-title 79
###begin article-title 80
###xml 15 44 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins
###end article-title 80
###begin article-title 81
###xml 136 165 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus
###end article-title 81
###begin article-title 82
###xml 0 29 <span type="species:ncbi:11673">Feline immunodeficiency virus</span>
Feline immunodeficiency virus infection: plasma, but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine
###end article-title 82
###begin article-title 83
###xml 22 57 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 96 101 <span type="species:ncbi:9606">human</span>
Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity
###end article-title 83
###begin article-title 84
###xml 52 87 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 103 108 <span type="species:ncbi:9606">human</span>
Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells
###end article-title 84
###begin article-title 85
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 14 34 <span type="species:ncbi:9534">African green monkey</span>
The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities
###end article-title 85
###begin article-title 86
Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain
###end article-title 86
###begin article-title 87
Capsid is a dominant determinant of retrovirus infectivity in nondividing cells
###end article-title 87
###begin article-title 88
###xml 0 3 <span type="species:ncbi:11673?1.0">FIV</span>
FIV Vectors
###end article-title 88
###begin article-title 89
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding
###end article-title 89
###begin article-title 90
TRIM5alpha selectively binds a restriction-sensitive retroviral capsid
###end article-title 90
###begin article-title 91
Multiple sequence alignment with the Clustal series of programs
###end article-title 91
###begin article-title 92
The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools
###end article-title 92
###begin article-title 93
SWISS-MODEL: an automated protein homology-modeling server
###end article-title 93
###begin article-title 94
SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modelling.
###end article-title 94
###begin article-title 95
Protein modeling by E-mail.
###end article-title 95

